SP13#4

General#

Cell Line

hPSCreg Name ESi006-A
Alternative name(s)
SP13#4
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 5th April 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Spanish Stem Cell Bank (ES)
Distributors
Derivation country Spain

External Databases

BioSamples SAMEA3303225
Cellosaurus CVCL_V203
EBiSC ESi006-A
ECACC 66540068

General Information

Publications
Projects
Is the cell line available in principle? Available with restrictions: Available for non-commercial research

Donor Information#

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Parkinson's disease
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Parkinson's syndrome
  • Parkinsons
  • Primary Parkinsonism
  • Parkinsons disease
  • Parkinson disease
  • Parkinson's disease (disorder)
  • Parkinson's disease NOS
  • Parkinson Disease, Idiopathic
  • PARKINSON DIS
  • Paralysis agitans
  • IDIOPATHIC PARKINSONS DIS
  • PARKINSON DIS IDIOPATHIC
  • Parkinsonism, Primary
  • Parkinson's Disease, Lewy Body
  • IDIOPATHIC PARKINSON DIS
  • Idiopathic PD
  • Idiopathic Parkinson Disease
  • Lewy Body Parkinson's Disease
  • Parkinsonian disorder
  • LEWY BODY PARKINSON DIS
  • Parkinson's
  • Idiopathic Parkinson's Disease
  • Parkinson's disease NOS (disorder)
  • Lewy Body Parkinson Disease
  • PARKINSONS DIS IDIOPATHIC
  • PARKINSONS DIS
  • Parkinson's Disease, Idiopathic
  • Parkinson syndrome
  • PARKINSONS DIS LEWY BODY
show more synonyms
Genetic variants
LRRK2 (target)
12q12
NM_198578.3:c.6055G>A
NP_940980.3:p.Gly2019Ser
G2019S
Disease associated phenotypes
  • Carrier of G2019S mutation in the LRRK2 gene

External Databases (Donor)

BioSamples SAMEA3303187

Ethics#

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Provide contact information of the holder of the original Donor Information Sheet:
Do you (Depositor/Provider) hold a copy of the SIGNED Donor Consent Form? Yes
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent pertain to a specific research project? Yes
Details on restriction to research project
Does consent permit unforeseen future research, without further consent? No
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? No
Does consent expressly permit collection of genetic information? Yes
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
Policy for access to genetic information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? No
Does consent permit access to any other source of information about the clinical treatment or health of the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Ethics Committee Center of Regenerative Medicine in Barcelona
Approval number
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Ethics Committee Center of Regenerative Medicine in Barcelona
Approval number
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation#

General

Source cell type
keratinocyte
An epidermal cell which synthesizes keratin and undergoes a characteristic change as it moves upward from the basal layers of the epidermis to the cornified (horny) layer of the skin. Successive stages of differentiation of the keratinocytes forming the epidermal layers are basal cell, spinous or prickle cell, and the granular cell.
Synonyms
  • malpighian cell
  • keratinized cell of epidermis
Age of donor (at collection) 65-69

Reprogramming method

Vector type Integrating
Vector Virus (Retrovirus)
Genes
Is the used vector excisable?
Unkown
Absence of reprogramming vector(s)?
Unkown
Reprogramming vectors silenced?

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Surface coating Gelatin
Feeder cells Human foreskin fibroblasts
Cellfinder Ont Id: CELDA_000001419
Passage method Mechanically
CO2 Concentration 5 %
Medium Other medium:
Base medium: Knockout DMEM
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
NEAA 1 %
Glutamax 2 mM
2-mercaptoethanol 50 µM
bFGF 10 ng/ml

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
Alkaline Phosphatase
Yes
NANOG
Yes
POU5F1 (OCT-4)
Yes
SSEA-3
Yes
SSEA-4
Yes
TRA 1-60
Yes
TRA 1-81
Yes
SOX2
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
In vitro spontaneous differentiation
Marker Expressed
AFP
Yes
FOXA2
Yes
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
In vitro spontaneous differentiation
Marker Expressed
SMA
Yes
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma
In vitro spontaneous differentiation
Marker Expressed
Tuj1
Yes
GFAP
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XX
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes